alcaftadine (Lastacaft) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG PubChem repoDB

Active Ingredient History

NOW
  • Now
Alcaftadine is a broad-spectrum antihistamine displaying a high affinity for histamine H1 and H2 receptors and a lower affinity for H4 receptors. It also exhibits modulatory action on immune cell recruitment and mast cell stabilizing effects. Alcaftadine is an inhibitor of the release of histamine from mast cells. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated. LASTACAFT® (alcaftadine ophthalmic solution) indicated for the prevention of itching associated with allergic conjunctivitis.   NCATS

Chemistry

  • SMILES: CN1CCC(CC1)=C2C3=NC=C(C=O)N3CCC4=C2C=CC=C4
  • InChIKey: MWTBKTRZPHJQLH-UHFFFAOYSA-N
  • Mol. Mass: 307.3895
  • ALogP: 2.78
  • ChEMBL Molecule:
    alcaftadine  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: No

Drug Pricing (per unit)

United States

$56.2333 - $75.6749
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

6,11-dihydro-11-(1-methyl-4-piperidinylidene)-5h-imidazo[2,1-b][3]benzazepine-3-carboxaldehyde | agn-229666 | alacaftadine | alcaftadina | alcaftadine | alcaftadinum | lastacaft | r89674 | r 89674 | r-89674 | vilasta

Organizations (11)

Research & Development (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (1)


 

Conjunctivitis, Allergic

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Conjunctivitis (Phase 4)

Conjunctivitis, Allergic ()

Healthy Volunteers (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial Organizations: 6

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue